Why uniQure Stock Is Crashing Today
Shares of uniQure NV (NASDAQ: QURE) are plummeting today, down by 40% as of 11:09 a.m. ET. The steep decline came after the company announced interim results from a phase 1/2 clinical study evaluating experimental gene therapy AMT-130 in treating Huntington's disease, a rare neurogenerative disease.
uniQure president of research and development Ricardo Dolmetsch stated that the company was "very pleased" with the interim results. So why did the biotech stock plunge? There were some concerns with the data for AMT-130.
For example, the group of patients treated with the high dose of AMT-130 experienced a 51.5% increase in neurofilament light chain (NfL) protein levels in their cerebrospinal fluid. Higher levels of NfL are viewed as a sign of deteriorating neurodegenerative disease.
Source Fool.com
